That “Too Good To Be True” Pharmacy Proposal On Your Desk

Michelle, the HR director for a 700-employee manufacturer, stared at a glossy PBM proposal promising $800,000 annual savings and “industry-leading” rebates. It all sounded great, until her CFO asked, “What are they actually changing, and how do we know these numbers are real?” She had no idea. The PBM rep kept talking about “value” and “proprietary networks,” but never dug into specifics. Michelle needed independent advice, not another pitch.

If you find yourself in Michelle’s shoes, you’re not alone. Choosing a pharmacy benefits consultant can make or break your plan’s savings, and your credibility with leadership. Some act as genuine fiduciary partners, dissecting your claim data and pushing back on PBMs. Others just repackage sales brochures. So how do you separate real pharmacy consulting from a thinly veiled PBM sales job?

Red Flags: How Sales Pitches Masquerade as Consulting

It’s not always obvious when a “consultant” is just echoing a PBM’s talking points. Here are signals you’re getting a sales pitch, not advice:

• Vague, unsubstantiated promises. “We’ll deliver the lowest net cost in the market.” Without showing you how, or benchmarking against your current PMPM or generic rate.
• Overemphasis on rebates or discounts alone. Focusing on “guaranteed rebates” instead of total net cost, ignoring utilization, and glossing over the cost of specialty drugs driving your spend.
• Single option or “preferred partner” recommendations. Steering you to a specific PBM (often CVS, OptumRx, or Express Scripts) without running a real RFP or showing bids from independents like Navitus, SmithRx, or Capital Rx.
• No review of your claims data. Proposing savings without analyzing your last 12-24 months of claims. If a consultant can’t explain your Humira spend or why your GDR is under 90%, they’re not doing the work.
• Resistance to transparency tools. Dismissing independent drug pricing sites like RxInfo.ai or consumer tools like RxSaver.ai, saying “our network is always cheaper.”

Real consulting means hard questions, not just rosy forecasts.

What Good Pharmacy Consulting Looks Like

You’ll know you’re working with a true advisor when they insist on starting with your actual data. A competent consultant will:

1. Request detailed claims files, including 12-24 months of pharmacy claims and medical data if specialty is a concern. This allows side-by-side analysis of your current PMPM (typical is $100-$140), generic dispensing rate (target 88-92%), and specialty as a percent of spend (usually 50-55%).
2. Benchmark your metrics against public sources and tools like RxPBM.ai for PBM contract terms, or RxInfo.ai for drug pricing. For example, if you’re paying $1,400/month for Humira when biosimilars are available for $800, you deserve to see those options.
3. Run a true market check, which means an RFP process open to both Big Three PBMs and independent/transparent models. The right consultant will show you bids from more than one PBM, ideally three or more.
4. Project disruption, so you know exactly how many members would change pharmacy, drug, or pay more/less, before you sign. They’ll spell out how a new exclusion list or a switch to biosimilars will hit your population by name and NDC, not just “minimal disruption.”
5. Explain practical implementation steps and help with employee communication. If your team is small, they’ll draft the HR emails for you.

You should come away with a clear understanding of specific savings opportunities, practical tradeoffs, and a mapped timeline for any switch. The right consultant isn’t afraid to tell you, “This switch saves $73,000 but will disrupt 27 people, and here’s how we’ll message it.”

Financial Scenario: Real Consulting in Action vs Sales Spin

Picture a 500-employee services company spending $1.35M on pharmacy, with a PMPM of $112 and a GDR of 91%. A consultant analyzes the claims and finds 19 patients on Humira ($34,000/year each), plus $280,000/year on GLP-1 drugs like Ozempic and Mounjaro. Their PBM “rebate” program still leaves them at $112 PMPM. In a real market check, the consultant brings in bids from OptumRx, Capital Rx, and Navitus. Capital Rx offers a biosimilar-preferred formulary at $87 PMPM, with a $650,000/year specialty copay assistance/accumulator program and 100% pass-through pricing.

That’s a concrete $150,000+ annual savings, after accounting for an estimated disruption to 14 Humira patients (shift to biosimilars) and 7 on brand insulin who could move to generics. The consultant provides an analysis showing the exact member impact, a draft HR communication plan, and a 90-day implementation roadmap. There’s no “trust us, it’ll be fine”, every number is checked and explained. This is what real consulting looks like. The PBM rep, by contrast, offered an “enhanced rebate” and vague “network savings”, but never asked for a detailed claims file or explained formulary differences.

The Single Most Actionable Step: Ask for a Claims-Based, Multi-Bid Market Check

This quarter, insist that any consultant you work with runs a full market check using your claims data as the foundation. Demand bids from at least three PBM options, including at least one independent or transparent PBM (not just the Big Three). Refuse to sign any “savings guarantee” or “exclusive network” deal that isn’t grounded in a review of your plan’s last 12-24 months of actual claims. If a consultant won’t do this, you’re getting a sales pitch, not real advice.

Want numbers to benchmark or tools for your own review? Sites like RxPBM.ai and RxInfo.ai offer independent PBM contract data and national drug pricing. Ground every contract and consultant engagement in your data, not just promises.